Eli Lilly fixes Mounjaro KwikPen to eliminate wasted medication doses

Eli Lilly has updated the Mounjaro KwikPen to address an issue with leftover medication. The previous version retained a small amount of the drug after the fourth injection, which had to be discarded. The revised pen will now fully empty after the final dose, preventing waste and potential overdosing concerns.

Mounjaro is a weekly treatment approved for two uses: managing type 2 diabetes and supporting weight loss. Its active ingredient, tirzepatide, works as both a GLP-1 and GIP analog, helping to lower blood sugar and reduce appetite.

The original KwikPen design left a residual volume after the fourth injection, which was not meant to be used. Patients had to dispose of the remaining medication, leading to inefficiency. Lilly has since redesigned the pen to ensure it is completely emptied after the final dose. The first shipments of the updated 15 mg quarterly packs will begin in January 2023. During the transition, both the old and new versions of the KwikPen will be available to patients.

The improved KwikPen eliminates the issue of leftover medication, ensuring patients receive the correct dosage every time. The change also removes the need to discard unused drug residue. Lilly’s update aims to make the treatment more efficient and reliable for users.